JO
SLN

John Overdeck’s Silence Therapeutics SLN Stock Holding History

John Overdeck’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33M Buy
121,004
+104,801
+647% +$737K ﹤0.01% 3384
2026
Q1 		$85.4K Sell
16,203
-23,141
-59% -$127K ﹤0.01% 4406
2025
Q4 		$239K Sell
39,344
-23,903
-38% -$153K ﹤0.01% 3692
2025
Q3 		$328K Buy
63,247
+3,935
+7% +$21.9K ﹤0.01% 3179
2025
Q2 		$344K Sell
59,312
-16,696
-22% -$71.6K ﹤0.01% 2740
2025
Q1 		$214K Sell
76,008
-66,044
-46% -$322K ﹤0.01% 2829
2024
Q4 		$977K Sell
142,052
-27,340
-16% -$353K ﹤0.01% 2195
2024
Q3 		$3.08M Buy
169,392
+70,285
+71% +$1.31M 0.01% 1376
2024
Q2 		$1.88M Sell
99,107
-8,105
-8% -$172K ﹤0.01% 1588
2024
Q1 		$2.32M Buy
+107,212
New +$2.33M 0.01% 1372

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

John Overdeck's SLN Position: Q2 2026 in Review

John Overdeck increased its Silence Therapeutics (SLN) stake by 647% in Q2 2026, buying an estimated $737K and bringing the position to 121,004 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #3384.

John Overdeck first reported a position in SLN in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.08M in Q3 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • John Overdeck held 121,004 shares of Silence Therapeutics worth $1.33M as of Q2 2026.
  • John Overdeck bought 104,801 Silence Therapeutics shares in Q2 2026, an estimated $737K.
  • Silence Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3384 holding.
  • John Overdeck first reported a position in Silence Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • John Overdeck's Silence Therapeutics position peaked at $3.08M in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.